CYNO Cynosure - Class A (MM)

Eclipse Medical will offer Cynosure's Smartlipo laser lipolysis system to physicians and spas in four southern states WESTFORD, Mass., Jan. 24 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that it has signed an exclusive distribution agreement for its Smartlipo(TM) laser lipolysis system with Eclipse Medical Ltd., a leading distributor of aesthetic high-tech medical devices and supplies. Under the three-year agreement, Eclipse Medical will have exclusive distribution rights for Smartlipo in a four-state region in the southern United States, including Texas, Louisiana, Arkansas and Oklahoma. Smartlipo(TM) is a new, innovative laser lipolysis system that provides aesthetic surgeons a less-invasive method for reducing fat cells. The Smartlipo LaserBodySculpting(SM) procedure enables aesthetic surgeons to treat localized deposits of fat through tissue coagulation, leading to skin tightening. "Eclipse Medical is one of the top U.S. distributors of aesthetic medical devices, and we are excited to partner with them," said Michael R. Davin, CEO of Cynosure. "This agreement greatly expands the reach of our newest flagship product -- Smartlipo. While Smartlipo is an emerging product, we have found that its launch has generated substantial interest among our target audiences. To capitalize on this demand, we are focused on identifying the most appropriate distribution channels for each geographic region. Although we expect the vast majority of our Smartlipo distribution will be direct, our agreement with Eclipse Medical affords us the ability to rapidly expand our presence in the southern U.S. market." Tom O'Brien, CEO of Eclipse Medical, said, "Offering leading-edge, breakthrough products to our clients is a fundamental part of Eclipse Medical's mission. With this agreement, we now have the opportunity to exclusively sell Cynosure's innovative Smartlipo product to our extensive network of physicians and spas. These customers can now offer their patients -- who may not be candidates for traditional liposuction -- a new minimally invasive option to help sculpt their bodies and achieve positive results." About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, remove unwanted fat and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosurelaser.com/. Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the future use and market acceptance of the Smartlipo laser lipolysis system, the ability of Eclipse Medical to successfully sell the Smartlipo laser lipolysis system, the markets in which Cynosure's products are sold, and other statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our history of operating losses, our reliance on sole source suppliers, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's Annual Report on Form 10-K filed with the SEC. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. 617-542-5300 DATASOURCE: Cynosure, Inc. CONTACT: Scott Solomon, Vice President, Sharon Merrill Associates, Inc., +1-617-542-5300, or , for Cynosure, Inc. Web site: http://www.cynosurelaser.com/

Copyright